O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm
Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm
discovery services to advance Karyopharm’s lead small molecule program toward the nomination
of a development candidate.
Dr. Sharon Shacham, cofounder and CSO of Karyopharm, said “O2h has an excellent reputation as an
efficient and high quality discovery services provider. We look forward to working with the O2h team
to further the progress of our first program as we continue to build our proprietary expertise
developing drugs targeting the nuclear pore complex machinery.
Sunil Shah, CEO of O2h, said “It has been a pleasure working with Dr. Shacham as she is one of the most
dynamic and focused drug discovery leaders that I have met. Leveraging Dr. Shacham’s proprietary and
proven approach to drug discovery, I’m optimistic that Karyopharm will be a great success.”
About Oxygen Healthcare Ltd
O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India.
The Indian operations provide a high level of chemistry expertise while the UK office provides project
management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology
companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a
particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h
include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services labunits
and ADME. Further information on O2h can be found at www.o2h.com.
